Abstract
Background: The emergence of infectious diseases and its resistance to approved drugs is a global threat to human health. The incidence of infectious diseases is increasing day by day and expected to rise exponentially in next 2 decades. Thus, there is a need for new treatment modalities for the treatment of microbial infections.
Methods: Thus, in the current investigation, we have explored the existing drugs [metformin (Anti-diabetic), propranolol (Anti-hypertensive) and amitriptyline (antidepressant)] for treatment of infectious diseases.
Results: An in-silico result of current investigation has shown the good interaction of metformin, propranolol, and amitriptyline towards various targets (Beta-lactamase, Penicillin-binding proteins, Staphylokinase protein, Oxidoreductase protein, etc.) of gram positive and gram negative bacteria as that of internal ligand. Further, in-vitro results have shown that the antibacterial activity of metformin, propranolol, and amitriptyline against Bacillus pumilus, Pseudomonas aeruginosa and Staphylococcus aureus.
Conclusion: The parameters such as Microtiter assay: percentage growth retardation and bacterial growth kinetics, Minimum inhibitory concentration (MIC), Post-antibiotic assay and Biofilm formation have indicated the antibacterial potential of metformin, propranolol, and amitriptyline. However, before starting a clinical trial, complete safety and efficacy profile of drugs in the treatment of infectious diseases should be investigated.
Keywords: Infectious diseases, drug repurposition, In silico, In vitro studies, bacterial infections, metformin, propranolol.
Graphical Abstract
[http://dx.doi.org/10.1016/j.arcmed.2005.03.041] [PMID: 16216650]
[http://dx.doi.org/10.1016/S0140-6736(06)68770-9] [PMID: 16731270]
[http://dx.doi.org/10.1038/nchembio.740] [PMID: 22173343]
[http://dx.doi.org/10.1097/IPC.0b013e318214b068]
[http://dx.doi.org/10.1080/10408398.2015.1077192] [PMID: 26464037]
[http://dx.doi.org/10.1086/595011] [PMID: 19035777]
[http://dx.doi.org/10.2174/1871526518666180806123230] [PMID: 30081793]
[http://dx.doi.org/10.1093/bib/bbv020] [PMID: 25832646]
[http://dx.doi.org/10.1002/dmrr.2975] [PMID: 29271563]
[http://dx.doi.org/10.20510/ukjpb/6/i1/173522]
[http://dx.doi.org/10.1590/S1517-83822010000300014] [PMID: 24031539]
[http://dx.doi.org/10.1016/S0168-1605(03)00160-0] [PMID: 15358511]
[http://dx.doi.org/10.1016/j.jep.2004.06.013] [PMID: 15325731]
[http://dx.doi.org/10.1016/j.ijantimicag.2010.05.006] [PMID: 20580208]
[http://dx.doi.org/10.2174/2211352516666180629124433]
[http://dx.doi.org/10.1128/AAC.00691-08] [PMID: 18955531]
[http://dx.doi.org/10.1186/1471-2180-11-54] [PMID: 21406118]
[http://dx.doi.org/10.1016/j.mimet.2007.11.010] [PMID: 18155789]
[PMID: 30179137]
[http://dx.doi.org/10.1056/NEJM197508072930606] [PMID: 1094291]
[http://dx.doi.org/10.1097/00004714-198502000-00003] [PMID: 3973067]
[http://dx.doi.org/10.1016/j.compbiolchem.2018.06.005] [PMID: 30067954]
[http://dx.doi.org/10.4103/2229-5186.93029]
[http://dx.doi.org/10.1016/j.carbpol.2011.08.024]
[http://dx.doi.org/10.4314/ahs.v17i3.24] [PMID: 29085409]
[http://dx.doi.org/10.1002/tox.20023] [PMID: 15269908]